SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
January 22, 1998
----------------
(Date of Report)
ENTROPIN, INC.
------------------------------------------------------
(Exact Name of Registrant as specified in its charter)
Colorado 33-23693 84-1090424
- ---------------------------- ------------ -------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
45926 Oasis Street, Indio, CA 92201
-----------------------------------------------------------
(Address of principal executive offices including zip code)
(760) 347-3369
---------------------------------------------------
(Registrant's telephone number including area code)
Vanden Capital Group, Inc.
1775 Sherman Street, Suite 1001, Denver, CO 80203
-------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
Item 5. Other Events.
- ---------------------
On January 22, 1998, the Registrant issued the following press release
relating to its acquisition of Entropin, Inc., a California corporation:
NEWS RELEASE
VANDEN CAPITAL GROUP, INC. ANNOUNCES
ACQUISITION OF ENTROPIN, INC.
FOR IMMEDIATE RELEASE
Denver, Colorado, January 22, 1998 -- Vanden Capital Group, Inc., a
Colorado corporation ("Vanden"), announced today that it had completed an
acquisition of Entropin, Inc., a California corporation ("Entropin"), effective
January 15, 1998. In connection with the acquisition, Vanden acquired all of the
outstanding shares of Entropin in exchange for shares of Vanden, resulting in
the shareholders of Entropin acquiring approximately 95% of the outstanding
voting shares of Vanden.
Subsequent to the acquisition, Vanden changed its name to Entropin, Inc.
and has become engaged in the pharmaceutical research business and will be
commercially developing a patented medicinal preparation known as Esterom(R),
which is the current business of Entropin. Esterom(R) is a medicinal preparation
formulated for the treatment of impaired range of motion associated with acute
lower back sprain and painful shoulder. Entropin has been issued seven patents
by the U.S. Patent Office on Esterom(R). Entropin has a current and open
Investigational New Drug File with the U.S. Food and Drug Administration and has
completed Phase II of the approval process.
The completion of the acquisition resulted in a change of control of the
Board of Directors and officers of Entropin. Higgins D. Bailey, Dewey H. Crim
and Donald Hunter have been elected as the Directors of Entropin. Daniel L.
Azarnoff, M.D. has been elected as Acting President, Higgins D. Bailey has been
elected as Chairman of the Board, Donald Hunter has been elected as ecretary and
Dewey H. Crim has been elected as Treasurer. Entropin's principal offices are
located at 45926 Oasis Street, Indio, California 92201.
For Further Information Contact:
Higgins D. Bailey, Chairman
Entropin, Inc.
(760) 347-3369
-2-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date: January 22, 1998 ENTROPIN, INC.
/s/ Higgins D. Bailey
By___________________________________________
Higgins D. Bailey
Chairman of the Board of Directors
-3-
